Peptika.
Cat. 06
Type I · Lyophilised
PK-2026-CAGRI-
Peptika Cagrilintide 5mg + Semaglutide 5mg vial vial
Lot-tracedEU pharmacyCold-chain 2–8 °C
N° 06 · Weight Management

Cagrilintide 5mg + Semaglutide 5mg vial.

Pre-compounded combination based on Cagrilintide.

Select strengthPer-vial price
Quantity
1
Total
€180.00· 1 vial

Build your bag, then either book a consultation (an EU-licensed physician reviews your file — anything declined is refunded) or upload an existing Rx at checkout.

  • ✓Magistral preparation — Directive 2001/83/EC Art. 5(1).
  • ✓Patient-named prescription only — dispensed against a valid Rx.
  • ✓EU-GMP Annex 1 Grade A/B cleanroom compounding.
  • ✓Cold-chain shipping across EU/EEA — 2–5 working days.
Overview

About Cagrilintide 5mg + Semaglutide 5mg vial.

A physician-directed, pre-compounded combination preparation. Each component is dosed by the prescribing physician; refer to the individual molecule monographs for mechanism and evidence. Nothing is dispensed without a validated prescription.

Mechanism of action

Combination preparation — see the individual component molecules.

Posology · for information only

Set by the prescribing physician.

Your physician sets the prescription. This is descriptive information, not a self-administration guide.

Storage

Lyophilised: store at 2–8 °C, protect from light. Once reconstituted: 2–8 °C, use within 30 days. Do not freeze.

Evidence baseClinical RCT evidence
Indications studied
Physician-directed combination protocol
Identification & specifications
INN / Name
Cagrilintide 5mg + Semaglutide 5mg vial
Form
Lyophilised vial · subcutaneous injection
Strength
5mg + Semaglutide 5mg vial
Manufacturing
EU-GMP Annex 1 · Grade A/B
Endotoxins
European Pharmacopoeia 2.6.14 · LAL assay
Identity & purity
HPLC + MS · > 98%
Cold chain
Validated 2–8 °C, monitored end-to-end
Regulatory basis
Directive 2001/83/EC · Article 5(1)
Logistics

2–5 working days

EU / EEA cold-chain delivery, 2–8 °C monitored end-to-end with digital temperature log. Tracking link sent on dispatch.

Legal status

Magistral preparation

Patient-named preparation under Directive 2001/83/EC Article 5(1). Dispensed exclusively against a valid EU prescription.

Cross-border

EU prescription recognition

Prescriptions written in one EU member state are recognised in others under Directive 2011/24/EU on cross-border healthcare.

Same therapeutic axis

Within Weight Management.

All Weight Management preparations
Pre-compounded

Other combinations.